Pre-emptive pharmacological inhibition of fatty acid–binding protein 4 attenuates kidney fibrosis by reprogramming tubular lipid metabolism
Open Access
- 3 June 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cell Death & Disease
- Vol. 12 (6), 1-14
- https://doi.org/10.1038/s41419-021-03850-1
Abstract
Kidney fibrosis is a hallmark of chronic kidney disease (CKD) progression that is caused by tubular injury and dysregulated lipid metabolism. Genetic abolition fatty acid-binding protein 4 (FABP4), a key lipid transporter, has been reported to suppress kidney interstitial fibrosis. However, the role and underlying mechanism of chemical inhibition of FABP4 in fibrotic kidney have not been well-documented. Here, we examined preemptive the effect of a FABP4 inhibitor, BMS309403, on lipid metabolism of tubular epithelial cells (TECs) and progression of kidney fibrosis. The expression of FABP4 was significantly elevated, concomitated with the accumulation of lipid droplets in TECs during kidney fibrosis. Treatment with BMS309403 alleviated lipid deposition of TECs, as well as interstitial fibrotic responses both in unilateral ureteral obstruction (UUO)-engaged mice and TGF-β-induced TECs. Moreover, BMS309403 administration enhanced fatty acid oxidation (FAO) in TECs by regulating peroxisome proliferator-activated receptor γ (PPARγ) and restoring FAO-related enzyme activities; In addition, BMS309403 markedly reduced cell lipotoxicity, such as endoplasmic reticulum (ER) stress and apoptosis in fibrotic kidney. Taken together, our results suggest that preemptive pharmacological inhibition of FABP4 by BMS309403 rebalances abnormal lipid metabolism in TECs and attenuates the progression of kidney fibrosis, thus may hold therapeutic potential for the treatment of fibrotic kidney diseases.Keywords
Funding Information
- National Natural Science Foundation of China (81800603)
- the longitudinal subproject of Naval Engineering University
This publication has 45 references indexed in Scilit:
- Chronic administration of BMS309403 improves endothelial function in apolipoprotein E‐deficient mice and in cultured human endothelial cellsBritish Journal of Pharmacology, 2010
- Regulation of basal cellular physiology by the homeostatic unfolded protein responseThe Journal of cell biology, 2010
- Endoplasmic reticulum stress in proteinuric kidney diseaseKidney International, 2010
- Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cellsThe FASEB Journal, 2009
- Proteinuria and Hyperglycemia Induce Endoplasmic Reticulum StressJournal of the American Society of Nephrology, 2008
- From endoplasmic-reticulum stress to the inflammatory responseNature, 2008
- Fatty acid-binding proteins: role in metabolic diseases and potential as drug targetsNature Reviews Drug Discovery, 2008
- Plasma Fatty Acid-Binding Protein 4 Increases with Renal Dysfunction in Type 2 Diabetic Patients without MicroalbuminuriaClinical Chemistry, 2008
- Regulation of Renal Fatty Acid and Cholesterol Metabolism, Inflammation, and Fibrosis in Akita and OVE26 Mice With Type 1 DiabetesDiabetes, 2006
- Effect of hereditary obesity on renal expressions of NO synthase, caveolin-1, AKt, guanylate cyclase, and calmodulinKidney International, 2005